Makoto Yamamoto

On September 2, 2026, our CEO Makoto Yamamoto presented at the DEEPTECH CATAPULT, a pitch competition held as part of the Industry Co-Creation (ICC) Summit KYOTO 2026 in Kyoto, Japan, and placed 2nd. The DEEPTECH CATAPULT gives companies building new industries on frontier technology seven minutes to present. Seven companies took the stage, and the rankings were decided by a vote of 35 judges. TKG Therapeutics received 27 points, placing 2nd. The presentation covered why we are building this...

We are pleased to announce that Makoto Yamamoto, CEO will present at “GTB / JBA / JETRO BioStartup Pitch – GTB BioStartup Connect” on December 11, 2025 . This event is jointly hosted by the Greater Tokyo Biocommunity (GTB), Japan Bioindustry Association (JBA), and JETRO, bringing together leading seed to Series C drug discovery startups. Our presentation will highlight our novel nucleic acid technology that induces cancer cell death and activates cancer immunity , forming a next-generation...

Our CEO, Makoto Yamamoto, has been invited to present at the “Rising Biotech Challenge 2025 DEMO DAY,” hosted by Plug and Play Japan. This event serves as the culmination of the TOKYO SUTEAM life science accelerator program, where selected startups and academic teams will showcase their scientific achievements and commercialization plans. Tokyo Nucleic Acid Synthesis will present its next-generation cancer immunotherapy platform based on hairpin DNA technology triggered by tumor-specific...